Fertility medicine has perfected a strange customer journey. First comes private doubt. Then months of calendar arithmetic. Then a thicket of unfamiliar initials - AMH, AFC, IUI, IVF, PGT - followed by a bill large enough to require its own counseling session. Onto Health’s sharpest idea is disarmingly small: give people a cheaper, calmer place to begin.
The company’s Onto Clarity program costs $99 in Illinois and Colorado. It includes an antral follicle count ultrasound, a short provider consultation and personalized guidance. Onto is careful about what it is not: a diagnosis, a complete workup or a promise. The next rung is a $300 new-patient consultation. From there the business becomes a full fertility practice, offering testing, timed intercourse, IUI, IVF, egg and embryo freezing, sperm preservation, optional embryo screening and frozen embryo transfer.
The product is a sequence, not a miracle
Onto’s clinical pitch is conventional where it should be. A patient begins with conversation and history, usually by virtual visit. Testing may include hormones, ultrasound, uterine imaging and semen analysis. Clinicians review the pattern, build a care plan and discuss the medical, emotional and financial tradeoffs before treatment. The company’s language repeatedly puts the patient “in the driver’s seat.” In an industry often accused of funneling anxious people toward the most intensive intervention, that phrasing earns its keep.
Its customers include couples trying to conceive, people planning years ahead, patients with recurrent loss or hormonal conditions, men seeking a fertility assessment, and people preserving eggs, embryos or sperm. Onto explicitly includes single parents, same-sex couples, donor conception and gestational-carrier paths. That breadth matters because fertility clinics are not merely baby factories. They are part laboratory, part procedural medicine, part genetic counseling, part logistics desk and, on a hard day, part emotional shock absorber.
The messy prehistory is the useful part
Onto did not arrive in a puff of founder mythology. Its corporate roots run through Mate Fertility, a company founded in 2020 to extend treatment into underserved markets through a distributed clinic model. A new investor group acquired Mate in April 2024. Brand strategists interviewed stakeholders, studied the category and produced the Onto name and identity. Public messaging then leaned toward technology, provider education and equipping generalist clinicians, who see many patients before a reproductive specialist ever does.
That was the first thesis to show strain. Distribution alone does not solve the workup. Generalists may be the front door, but fertility still demands specialist judgment, laboratories, imaging, monitoring and coordinated procedures. By early 2026, Onto’s public face had changed. Dr. Roohi Jeelani, a double board-certified reproductive endocrinologist and OB-GYN, announced herself as CEO and Founder. The company now foregrounds physician-led clinics in Chicago and suburban Denver, supported by virtual care and technology.
“We don’t start with a procedure. We start by understanding your unique fertility story.”Onto Health’s stated care philosophy
What changed their mind? No single public post provides a boardroom confession. The operating evidence is clearer than the rhetoric: Onto moved closer to the patient and deeper into the clinical workflow. Jeelani brings specialist credibility and the perspective of a former fertility patient. The company publishes prices, opens with assessment, and owns delivery in two markets. Then it bought software designed to make that delivery repeatable.
The $20 million software turn
In April 2026, ARTIS Ventures and Humania Capital co-led Onto’s $20 million Series A. Public funding databases also list an $8.2 million early round in 2024, bringing reported capital to roughly $28.2 million. The fresh money was earmarked for U.S. expansion and an entry into the Gulf Cooperation Council region, where Humania says its network spans 18 tertiary hospitals and more than 50 outpatient facilities.
Three months later, Onto acquired LEVY Health. The acquired platform structures patient intake, helps clinicians identify endocrine disorders and streamlines fertility workups. Onto calls it a technology engine. That is more concrete than the usual “AI-enabled” garnish: the software sits before and between expensive clinical decisions, where a cleaner history and more consistent reasoning can save time. Onto also says LEVY can help other practices add lower-complexity fertility care, opening a B2B route alongside revenue from its own clinics.
The business now has three layers. Consumer services create the relationship. Clinics deliver diagnostics and treatment. Software turns intake and clinical pathways into infrastructure that can travel. The longevity theme ties those layers together: Onto argues that fertility is not an isolated episode but a signal about hormones, metabolic health and well-being across the lifespan.
The bill is part of the product
Fertility pricing has a talent for becoming abstract just as the numbers become frightening. Onto takes a more retail approach for selected services. Beyond the $99 Clarity visit and $300 consultation, its public list shows a frozen embryo transfer package at $5,500 in Illinois and $4,950 in Colorado. A microfluidic sperm-sorting add-on is listed at $400 and $300, respectively. Prices vary because laboratories, staffing and local operating costs vary. Medication, outside services and certain lab fees may sit outside a package.
That transparency solves one problem and exposes another. A menu price cannot predict the final bill for a patient whose protocol changes, whose insurer covers medication but not procedures, or whose embryos require additional work. Onto offers financial counseling, accepts insurance depending on market and plan, and lists PatientFi, Gaia, Egg Fund and CapexMD as financing options. The practical promise is not “fertility care is cheap.” It is “you should know the next number before you consent to it.”
This is also the commercial funnel. A low-cost assessment can acquire a curious customer years before IVF. A consultation can lead to diagnostics. Diagnostics may lead to monitoring, preservation or treatment. Each step produces revenue, but it also produces a decision point where the patient can stop. That last feature is important. The model earns trust only if “no treatment yet” is allowed to be a successful outcome.
On the enterprise side, LEVY gives Onto a second way to grow. Rather than opening every clinic itself, the company can equip other practices with structured intake and workup support. In theory, software improves consistency while partner clinics add geographic reach. In practice, this hybrid is operationally fussy: owned clinics, licensed medicine, laboratories, payer contracts and software sales each run on different clocks. The prize is a care network with more reach than its real-estate footprint. The risk is becoming three companies wearing one very elegant name.
What a founder can steal
Make the first yes cheap, specific and honest.
- Package the first useful step. “Ultrasound plus guidance for $99” is easier to buy than “begin your fertility journey.”
- Publish the boundary. Onto says Clarity is a snapshot, not a complete diagnosis.
- Own the handoff. The assessment leads into testing, planning and treatment inside one system.
- Put software where professionals lose time. Intake and workup support are less theatrical than an AI doctor, and more plausible.
This playbook works when the first service produces genuine information, the company can fulfill the next step, and customers trust the professional behind it. It fails when a low-priced assessment becomes a disguised sales appointment, when clinics lack local capacity, or when the software standardizes away clinical nuance. It also gets harder across borders. Regulations, laboratory standards, insurance, cultural expectations and family law do not travel as neatly as a slide deck.
Onto’s “whole-person” language creates another condition: prove it. Peptides and longevity protocols may appeal to patients, but evidence quality varies by intervention. A careful fertility company has to separate supportive wellness from established reproductive medicine with unusual clarity. The brand’s credibility will depend on how visibly it draws that line.
Where Onto fits
The market is crowded from every angle. Kindbody, CCRM, RMA and Inception operate large fertility networks. Progyny and Carrot organize benefits. Modern Fertility made at-home testing legible. Independent reproductive endocrinologists still provide much of the relationship-driven care. Onto’s difference is the combination: owned clinics, an inexpensive front door, published pricing, inclusive family-building, a longevity frame and now an acquired decision-support system.
There is no public revenue figure, valuation or patient count. Two clinic markets are still two clinic markets. The LEVY acquisition is a strategy, not proof that integration works. Yet Onto has made one valuable correction already: access is not only a map problem. It is a timing problem, a comprehension problem and a coordination problem. The company’s bet is that people will ask earlier if the first answer is affordable, and stay if the next answer feels personal.
Keep going